



# **10<sup>TH</sup> WORLD CONGRESS OF MELANOMA** IN CONJUNCTION WITH **17<sup>TH</sup> EADO CONGRESS**



**APRIL  
14-17  
2021**

(LATEST UPDATE: 10/06/2020) **PRELIMINARY PROGRAMME**

**WORLDMELANOMA2021.COM**  
ROMA CONVENTION CENTER, LA NUVOLA  
ROME, ITALY









## Table of Contents

<b>Welcome Message</b>	<b>5</b>
<b>Congress Information</b>	<b>6</b>
Committees	7
Call for Abstracts	9
General Information A–Z	10
Floor Plan	16
<b>Scientific Programme</b>	<b>19</b>
Wednesday, April 14	20
Thursday, April 15	30
Friday, April 16	40
Saturday, April 17	50
<b>Sponsored Symposia</b>	<b>58</b>
<b>Sponsors</b>	<b>59</b>

### Important Deadlines

<b>October 31, 2020</b>	Early registration fee deadline
<b>January 6, 2021</b>	Deadline for abstract submission
<b>January 20, 2021</b>	Notification of acceptance of abstracts





Paolo Ascierto



Ketty Peris



Claus Garbe



Mario Santinami



Axel Hauschild







## Welcome Message

Dear colleagues and friends,

We have the great honour and pleasure to invite you to join us for the **10<sup>th</sup> World Congress of Melanoma in conjunction with the 17<sup>th</sup> EADO Congress** which will be held under the auspices of the Melanoma World Society (MWS) and European Association of Dermato-Oncology (EADO).

The first World Congress of Melanoma took place in Venice in 1985. Since then the conference has become a well-established meeting which is held every four years. **In 2021 the event will celebrate its tenth anniversary** and we are very pleased that the congress will return to Italy for this meeting.

The scientific programme will provide **rich educational opportunities for all delegates**. The field of melanoma will be covered as well as Squamous Cell Carcinoma (SCC), Merkel Cell Carcinoma (MCC), Basal Cell Carcinoma (BCC), Actinic Keratosis, Cutaneous Sarcoma and Cutaneous T- and B-Cell Lymphoma.

The congress offers a great opportunity for young doctors and researchers to familiarize themselves with melanoma and non-melanoma skin cancers. The entire spectrum of questions related to melanoma and non-melanoma skin cancers will be covered. Epidemiology, prevention and early detection, diagnostics and staging, surgical and radiotherapy and systemic and intralesional therapies are core themes of the meeting.

**Rome, the host city, is one of the most attractive cities in the world and a major touristic hotspot for visitors from anywhere.** We are confident that the World Congress will represent unforgettable professional and personal experience for all delegates and we look forward to welcoming you in Rome!



Prof. Paolo Ascierto  
Congress President



Prof. Claus Garbe  
Congress President



Prof. Axel Hauschild  
Congress President



Prof. Ketty Peris  
Congress President



Prof. Mario Santinami  
Congress President



## Congress Information

COMMITTEES

CALL FOR ABSTRACTS

GENERAL INFORMATION A–Z

FLOOR PLAN

# COMMITTEES

## Congress Presidents

Paolo **Ascierto**, Naples, Italy  
Claus **Garbe**, Tuebingen, Germany  
Axel **Hauschild**, Kiel, Germany  
Ketty **Peris**, Rome, Italy  
Mario **Santinami**, Milan, Italy

## Congress Faculty

### A

Sanjiv **Agarwala**, Philadelphia, USA  
Joseph **Alcalay**, Tel Aviv, Israel  
Salvador Martin **Algarra**, Pamplona, Spain  
Robert **Andtbacka**, Edison, USA  
Martina **Angi**, Milan, Italy  
Ana **Arance**, Barcelona, Spain  
Guiseppe **Argenziano**, Naples, Italy  
Paolo **Ascierto**, Naples, Italy

### B

Carlos **Barcaui**, Rio de Janeiro, Brazil  
Lars **Bastholt**, Odense, Denmark  
Boris **Bastian**, San Francisco, USA  
Veronique **Bataille**, London, United Kingdom  
Jürgen **Becker**, Essen, Germany  
Carola **Berking**, Erlangen, Germany  
Christian **Blank**, Amsterdam, The Netherlands  
Anja **Bosserhoff**, Erlangen, Germany  
Matilda **Bylaitė-Bučinskienė**, Vilnius, Lithuania

### C

Nathalie **Cassoux**, Paris, France  
Gabriela **Cinat**, Buenos Aires, Argentina  
Pippa **Corrie**, Cambridge, United Kingdom

### D

Michael **Davies**, Houston, USA  
Veronique **Del Marmol**, Brussels, Belgium  
Lev **Demidov**, Moscow, Russia  
Brigitte **Dreno**, Nantes, France  
Reinhard **Dummer**, Zurich, Switzerland

### E

Alexander **Eggermont**, Utrecht, The Netherlands  
Thomas **Eigentler**, Tuebingen, Germany

### F

Maria Concetta **Fargnoli**, L'Aquila, Italy  
Ana-Maria **Forsea**, Bucharest, Romania

### G

Thomas **Gajewski**, Chicago, USA  
Claus **Garbe**, Tuebingen, Germany  
Christoffer **Gebhardt**, Hamburg, Germany  
Jeffrey **Gershenwald**, Houston, USA  
Helen **Gogas**, Athens, Greece  
Stephan **Grabbe**, Mainz, Germany  
Jean Jacques **Grob**, Marseille, France  
Samantha **Guild**, Richmond, USA  
Jun **Guo**, Beijing, China  
Ralf **Gutzmer**, Hanover, Germany

### H

John **Haanen**, Amsterdam, The Netherlands  
Allan C. **Halpern**, New York, USA  
Holger **Hänßle**, Heidelberg, Germany  
Catherine **Harwood**, London, United Kingdom  
Jessica **Hassel**, Heidelberg, Germany  
Axel **Hauschild**, Kiel, Germany  
Nicholas **Hayward**, Brisbane, Australia  
Christoph **Höller**, Vienna, Austria

### I

Taiki **Isei**, Osaka, Japan

### K

Katharina **Kähler**, Kiel, Germany  
Lidija **Kandolf-Sekulovic**, Belgrade, Serbia  
Alexander **Katalinic**, Luebeck, Germany  
Roland **Kaufmann**, Frankfurt, Germany  
Nicole **Kelleners-Smeets**, Maastricht  
The Netherlands  
Harald **Kittler**, Vienna, Austria

### L

Aimilios **Lallas**, Thessaloniki, Greece  
Maria Teresa **Landi**, Bethesda, USA  
Céleste **Lebbe**, Paris, France  
Ulrike **Leiter**, Tuebingen, Germany  
Mitch **Levesques**, Zurich, Switzerland  
Elisabeth **Livingstone**, Essen, Germany  
Georgina **Long**, Sydney, Australia  
Caterina **Longo**, Reggio Emilia, Italy  
Paul **Lorigan**, Manchester, United Kingdom



**M**

Marcus **Maia**, São Paulo, Brazil  
 Michele **Maio**, Siena, Italy  
 Josep **Malveyh**, Barcelona, Spain  
 Mario **Mandalá**, Bergamo, Italy  
 Richard **Marais**, Manchester, United Kingdom  
 Grant **McArthur**, Melbourne, Australia  
 Martin **McMahon**, Salt Lake City, USA  
 Friedegund **Meier**, Dresden, Germany  
 Olivier **Michielin**, Lausanne, Switzerland  
 Mark **Middleton**, Oxford, United Kingdom  
 Zeljko **Mijuskovic**, Belgrade, Serbia  
 Peter **Mohr**, Buxtehude, Germany  
 David **Moreno-Ramirez**, Seville, Spain  
 Rodrigo R. **Munhoz**, São Paulo, Brazil

**N**

Paul **Nathan**, London, United Kingdom  
 Bart **Neyns**, Brussels, Belgium  
 Paul **Nghiem**, Seattle, USA  
 Van **Anh Nguyen**, Innsbruck, Austria

**O**

Judit **Oláh**, Szeged, Hungary  
 Friedrich **Overkamp**, Berlin, Germany

**P**

Giovanni **Pellacani**, Modena, Italy  
 Ketty **Peris**, Rome, Italy  
 Teresa **Petrella**, Toronto, Canada  
 Michael **Postow**, New York, USA  
 Susana **Puig**, Barcelona, Spain

**Q**

Pietro **Quaglino**, Turin, Italy  
 Paola **Queirolo**, Genova, Italy

**R**

Bernardo **Rapoport**, Johannesburg, South Africa  
 Erika **Richtig**, Graz, Austria  
 Jason **Rivers**, Vancouver, Canada  
 Caroline **Robert**, Paris, France  
 Merrick **Ross**, Houston, USA  
 Piotr **Rutkowski**, Warsaw, Poland

**S**

Philippe **Saiag**, Boulogne Billancourt, France  
 Mario **Santinami**, Milan, Italy  
 Jakob **Schachter**, Tel Aviv, Israel  
 Dirk **Schadendorf**, Essen, Germany  
 Bastian **Schilling**, Wuerzburg, Germany  
 Chrysalyne **Schmuls**, Boston, USA  
 Richard **Scolyer**, Sydney, Australia  
 Marisol **Soengas**, Madrid, Spain  
 Vernon **Sondak**, Tampa, USA  
 Hans Peter **Soyer**, Brisbane, Australia  
 Gilliosa **Spurrier**, Teilhet, France  
 Andreas **Stang**, Essen, Germany  
 Eggert **Stockfleth**, Bochum, Germany  
 Alexander **Stratigos**, Athens, Greece  
 Somasundaram **Subramanian**, Moscow, Russia  
 Inge Marie **Svane**, Copenhagen, Denmark

**T**

Alessandro **Testori**, Milan, Italy  
 Luc **Thomas**, Lyon, France

**U**

Selma **Ugurel**, Essen, Germany  
 Jochen **Utikal**, Mannheim, Germany

**V**

Alexander **van Akkooi**, Amsterdam  
 The Netherlands  
 Ricardo **Vieira**, Coimbra, Portugal  
 Amaya **Viros**, Manchester, United Kingdom

**W**

Alberto **Wainstein**, Belo Horizonte, Brazil  
 Jennifer **Wargo**, Houston, USA  
 Jeffrey **Weber**, New York, USA  
 Michael **Weichenthal**, Kiel, Germany  
 Dagmar **Whitaker**, Cape Town, South Africa  
 David **Whiteman**, Brisbane, Australia  
 Jedd **Wolchok**, New York, USA

**Z**

Iris **Zalaudek**, Trieste, Italy



# CALL FOR ABSTRACTS

## Abstract Submission Deadline: January 6, 2021

All those interested in presenting abstracts at the 10<sup>th</sup> World Congress of Melanoma and 17<sup>th</sup> EADO Congress are invited to submit their work to the Programme Committee for review.

Notification of Acceptance of Abstracts: January 20, 2021

## Abstract Topics

- › Actinic keratoses
- › Basal cell carcinoma
- › Cutaneous sarcoma
- › Cutaneous T- and B-cell lymphoma
- › Melanoma
- › Merkel cell carcinoma
- › Rare tumors
- › Squamous cell carcinoma

## Abstract Guidelines

- › Abstracts may be submitted online at <https://worldmelanoma2021.com/call-for-abstracts/abstract-submission/>. Abstracts submitted by fax or e-mail will not be accepted.
- › Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
- › Please indicate the topic from the abstract topics list and your preferred type of presentation (oral or poster). The Committee will endeavor to schedule abstracts according to authors' preferences but reserves the right to decide on the final form of presentation. Encore abstracts will be accepted.
- › Please structure the abstract as follows: Background, Methods, Results, Conclusions. The text shall not exceed 4000 characters including spaces.
- › It is acceptable to include up to two tables or graphics as part of the abstract.
- › All abstracts must be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. Abstracts will not be edited by the Congress Secretariat prior to publication, therefore please check the grammar and spelling carefully.
- › We kindly ask authors to not use any commercial names of medications or drugs, but rather to use generic names instead.

## Oral Presentations

Selected abstracts will be chosen for an oral presentation during the free communications sessions.

## E-Poster Presentation

Abstracts selected for poster will be presented as e-Posters during the congress. Approximately ten e-Poster terminals will be available for viewing in the e-Poster area. E-posters must be uploaded before the congress to be visible at the terminals. The file must be submitted in jpg format (1920x1080 pixels). Further information will be provided prior to the congress.

## Registration

Please note that the acceptance of an abstract does not include the congress registration. The presenting author must be a registered participant, otherwise the abstract will not be reviewed and waived from the programme.

# GENERAL INFORMATION A–Z

## Accommodation

A limited number of rooms at selected hotels close to the conference venue La Nuvola has been reserved at reduced rates. Please contact for your individual housing reservation your preferred accommodation among one of the following hotels below. **In order to receive the discount, please state the keyword "World Congress of Melanoma 2021" when booking!**

Kindly note that all hotels have limited capacity, so please book at your earliest convenience.

Stars	Location	Distance to Congress Venue	Discounted Congress Rate incl. VAT**	City Tax per Night*	Booking Method
<b>Hilton Rome EUR – La Lama</b>					
4	EUR District	0,1 km	253 € Standard 275 € Deluxe 330 € Executive	6 €	tbc - Opening 2020
<b>Ibis Styles Roma EUR</b>					
4	EUR District	2,0 km	160 €	6 €	Contact: Ms. Anna Maria Romani Email: <a href="mailto:H9301-RM@ACCOR.COM">H9301-RM@ACCOR.COM</a> Phone: +39 06 94442000
<b>Mercure Roma West</b>					
4	EUR District	7,5 km	110 €	6 €	Contact: Ms. Susanna Macciocchi Email: <a href="mailto:groups@mercureromawest.com">groups@mercureromawest.com</a> Phone: +39 06 508 34 715
<b>Michelangelo Rome</b>					
4	Trastevere	10 km	240 €	6 €	Contact: Mr. Stefano Iuliano, Email: <a href="mailto:reservations.metropole.rm@starhotels.it">reservations.metropole.rm@starhotels.it</a> Phone: +39 06 47741
<b>Novotel Roma EUR</b>					
4	EUR District	2,0 km	160 €	6 €	Contact: Ms. Alessia Russo Email: <a href="mailto:H9299-SL@ACCOR.COM">H9299-SL@ACCOR.COM</a> Phone: +39 06 592801
<b>Shangri-La Roma</b>					
4	EUR District	2,2 km	100 €	6 €	Contact: Mr. Marco Capitani Email: <a href="mailto:marcocapitani@shangrilaroma.it">marcocapitani@shangrilaroma.it</a> Phone: +39 06 591 6441
<b>Sheraton Parco de' Medici Rome Hotel</b>					
4	EUR District	10 km	187 €	6 €	<a href="#">Online Booking System</a>

\* City tax may increase until 2021.

\*\* Double room single use, breakfast included.



### Badges

The name badge is the official congress identification document. Please wear your badge at all times in order to gain entry into the session rooms and exhibition area. Admission to the congress area will not be permitted without badge identification. Kindly note that for the reprinting of lost or forgotten badges, an administrative fee of 20 Euro will be charged.

### Cancellation Policy

Cancellations must be received in writing by December 14, 2020. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to: [registration@worldmelanoma2021.com](mailto:registration@worldmelanoma2021.com).

### Certificate of Attendance

The Certificates of Attendance can be downloaded during the congress from the self-registration desks. Alternatively, the certificate can be downloaded in the personal user area of your registration account from Monday, April 19, 2021 onwards.

### Cloakroom and Luggage

The cloakroom is located next to the congress bags desk, please refer to the floor plan for orientation. As storage space is limited, we recommend all guests to store their baggage at the hotel. Please note that the organizer and the congress venue will not accept any liability for any items left behind.

### CME Credits

An application for CME accreditation will be made. To obtain the CME certificate, the evaluation form must be filled out online in the personal user area. You will receive your CME certificate by email approximately 90 days after the congress.

### Congress App

An app will be available for the congress. Further information will follow shortly.

### Congress Bag

Congress bags can be picked up from the Congress Bag Desk which is located at the entrance to the meeting rooms. Please refer to the floor plan for orientation and present your badge to receive your bag. Each congress bag contains a copy of the Final Programme and other useful information.

#### Congress Organization

##### MedConcept

Gesellschaft für medizinische Projekte mbH  
Friedenstr. 58  
15366 Neuenhagen bei Berlin  
Germany

Phone +49 (0)3342 4268930

Fax +49 (0)3342 4268940

Responsible Project Manager: Mrs. Mirja Christ

Email: [congress@worldmelanoma2021.com](mailto:congress@worldmelanoma2021.com)

[www.medconcept.org](http://www.medconcept.org)

**Congress Venue****Roma Convention Center**

La Nuvola

Viale Asia snc

00144 Rome

Italy

<http://www.romaconventiongroup.it/en/visitors/>**Exhibition**

A commercial exhibition will run during the congress.

**Exhibition Opening Hours**

Wednesday, April 14	11:00–20:00
---------------------	-------------

Thursday, April 15	07:45–17:45
--------------------	-------------

Friday, April 16	07:45–18:00
------------------	-------------

Saturday, April 17	07:45–13:30
--------------------	-------------

**First Aid**

In case of emergency, please go to the First Aid room which is located on the main level next to the Congress Bag Desk. The Italian number for the ambulance service is 118.

**Insurance**

The organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance.

**Invitation Letter**

The congress organizers would be pleased to send a formal letter of invitation to delegates who require an invitation letter for visa purposes. It is understood that such an invitation is intended to help potential delegates obtain a visa or to raise funds. The letter of invitation does not imply a commitment from the congress to provide any financial support.

To receive your invitation letter, please send an email including your full address and passport details to [registration@worldmelanoma2021.com](mailto:registration@worldmelanoma2021.com).

**Language and Translation**

The official language of the meeting is English. Simultaneous translation will not be provided.

**Liability Disclaimer**

In the unlikely occurrence that the congress must be cancelled or postponed due to circumstances beyond the control of the organizers (natural disasters, political, social or economic events or other unforeseen events beyond control), the organizers cannot be held liable for any costs incurred by the event attendee. The organizers will record images during the event. By virtue of attendance, attendees agree to the organizers usage of these recordings on the website and for marketing.



### Lost and Found

Please hand in all found items at the registration desk. A lost and found box will be provided there.

### Networking Evening

All registered delegates are invited to join the networking evening on Wednesday, April 14, 2021 from 18:00–20:00 which will be held within the Industry Exhibition.

### Parking Facilities

About 200 free parking spaces are available at the congress venue “La Nuvola” (entry height: 2.20 meters).

### Programme Changes

The organizer reserves the right to make changes to the event programme at short notice if necessary. This does not result in any reimbursement claims. Programme changes will be announced during the congress.

### Registration

Registration is only possible by using the online portal on the congress website:

<https://worldmelanoma2021.com/registration/individual-registration/>.

Group registrations are possible from 5 persons and can also only be booked online:

<https://worldmelanoma2021.com/registration/group-registration/>

Category / Prices	Early Fee until October 31, 2020	Regular Fee from November 1 – January 31, 2021	Late Fee from February 1, 2021
Full Delegate / Medical Doctor	650 €	750 €	900 €
EADO Member	550 €	650 €	800 €
Resident / Trainee / Medical Fellow	550 €	650 €	800 €
Scientist / Allied Health Professional	550 €	650 €	800 €
Student / Nurse*	150 €	175 €	200 €
Day Tickets	250 €	250 €	250 €
Public Transportation Ticket	24 €	24 €	24 €

\* The student/nurse registration rate will be granted only after receipt of proof of ID.  
The proof of ID can be uploaded online during the registration process.

**Registration fee covers:**

- › Admission to scientific sessions and satellite symposia
- › Admission to the industrial exhibition
- › Congress bag
- › Opening ceremony and welcome reception
- › Certificate of attendance
- › Collection of abstracts

**Method of payment:**

Only credit cards (Visa, MasterCard, American Express) will be accepted. Bank transfers are only possible in exceptional cases for group bookings/hospitals. Please note that in payments by bank transfers, the bank charges must be paid by the delegate.

**Registration and Information Desk**

The registration desk is situated at the main entrance of the congress venue La Nuvola.

**Opening Hours:**

Wednesday, April 14	09:00–20:00
Thursday, April 15	07:00–18:00
Friday, April 16	07:00–18:00
Saturday, April 17	08:00–13:30

**Smoking**

Smoking is strictly forbidden within the congress center.

**Speaker Preview Room**

There will be a Speakers' Preview Room provided for all speakers. The Speakers' Preview Room is located at the Mezzanine Level.

**Opening Hours:**

Wednesday, April 14	10:00–18:00
Thursday, April 15	07:00–18:00
Friday, April 16	07:00–18:00
Saturday, April 17	08:00–13:00

**The following facilities will be provided in the room:**

- › computers (Windows operating system) to review, alter and upload the presentations to the server
- › support by technical staff is available

The conference staff will transfer the presentation from the Speakers' Preview Room to the corresponding session rooms. The presentations should be handed in to the Speakers' Preview Room **at least two hours before the session**. Speakers with a presentation during the first time slot of the morning are kindly asked to hand in their presentation the day before. All speakers will be able to find their presentations easily on the preview monitor on the lectern in the corresponding session room.



### Sustainability

Sustainability is more important today than ever before. We are working internally on increasing our sustainability efforts and would like to encourage all involved in the 10<sup>th</sup> World Congress of Melanoma / 17<sup>th</sup> EADO Congress to minimize their environmental and social impacts. Go Green – Acting today for tomorrow!

### Ways to get involved

- › Travel by train / by carbon offsetting your flights to Rome and encourage your colleagues to do the same
- › Use the recycling bins provided on-site
- › Recycle your name-badge in the bin provided at the registration desk
- › Recycle all brochures and promotional items not needed in the bin provided within the industrial exhibition
- › Use the public transportation system in Rome

### Time Zone

Rome is in the Central European Time Zone which is 1 hour ahead of Greenwich Mean Time (GMT+1). Like most states in Europe, Rome observes daylight saving (summer time). On Sunday, 28 March 2021 time will be shifted forward by 1 hour (GMT+2).

### Weather

April is a great months to visit Rome. The average maximum temperature lies around 18 °C.

### Wi-Fi

Free internet access will be available within the congress area.


Please use the following access codes to login:

**Network: WCM Rome**


**Password: WCM-2021**

# FLOOR PLAN

## MAIN LEVEL -1



## MEZZANINE LEVEL











## Scientific Programme

WEDNESDAY, APRIL 14

THURSDAY, APRIL 15

FRIDAY, APRIL 16

SATURDAY, APRIL 17

# Scientific Programme

WEDNESDAY, APRIL 14

SCIENTIFIC PROGRAMME

	ROME	PARIS	LONDON
11:00			
12:00	<b>12:00–12:15</b> Welcome		
	<b>12:15–13:15</b> Plenary Lecture <b>PL01</b> Diagnostics		
13:00			
	<b>13:15–14:45</b> Symposium <b>SY01</b> Dermoscopy 1: Dermoscopy in melanoma management	<b>13:15–14:45</b> Symposium <b>SY02</b> Artificial intelligence in medical oncology, pathology and radiology	<b>13:15–14:45</b> Symposium <b>SY03</b> Epidemiologic trends in melanoma
14:00			
	<b>14:45–15:15</b> Coffee Break		
15:00			
	<b>15:15–16:45</b> Symposium <b>SY06</b> Dermoscopy 2: Difficult clinical scenarios	<b>15:15–16:45</b> Symposium <b>SY07</b> Surgery of metastatic melanoma	<b>15:15–16:45</b> Symposium <b>SY08</b> Squamous cell carcinoma: epidemiology and management
16:00			
	<b>16:45–17:00</b> Coffee Break		
17:00	<b>17:00–18:00</b> Satellite Symposium <b>SAT01</b>	<b>17:00–18:00</b> Satellite Symposium <b>SAT02</b>	<b>17:00–18:00</b> Satellite Symposium <b>SAT03</b>
18:00			
19:00	<b>18:00–20:00</b> Welcome Reception		
20:00			



# WEDNESDAY APRIL 14

COPENHAGEN

AMSTERDAM

DUBLIN

			11:00
			12:00
			13:00
13:15–14:45	13:15–14:45		
<b>Symposium SY04</b> Actinic keratosis: recent treatment developments	<b>Symposium SY05</b> Melanoma pathology – genomics and morphology		14:00
			15:00
15:15–16:45	15:15–16:45	15:15–16:45	
<b>Symposium SY09</b> Immunotherapies beyond checkpoint inhibition	<b>Symposium SY10</b> Genetic susceptibility of melanoma and cancer syndromes	<b>Symposium SY11</b> Registries for real world treatment data and outcome research	16:00
			17:00
17:00–18:00	17:00–18:00	17:00–18:00	
<b>Satellite Symposium SAT04</b>	<b>Satellite Symposium SAT05</b>	<b>Satellite Symposium SAT06</b>	18:00
			19:00
			20:00

WEDNESDAY, APRIL 14

SCIENTIFIC PROGRAMME

## WEDNESDAY, APRIL 14

12:00–12:15  
ROME

## Welcome

12:15–13:15 PL01  
ROME

## Plenary Lecture Diagnostics

Chairpersons: Paolo Ascierto, Naples, Italy  
Ketty Peris, Rome, Italy

**12:15–12:45 Why dermoscopy?**  
Giuseppe Argenziano, Naples, Italy

**12:45–13:15 From ugly duckling to artificial intelligence**  
Jean Jacques Grob, Marseille, France

13:15–14:45 SY01  
ROME

## Symposium Dermoscopy 1: Dermoscopy in melanoma management

Chairpersons: Carlos Barcaui, Rio de Janeiro, Brazil  
Iris Zalaudek, Trieste, Italy

**13:15–13:30 Does dermoscopy save lives?**  
Harald Kittler, Vienna, Austria

**13:33–13:48 Clinical clues for melanoma diagnosis**  
Iris Zalaudek, Trieste, Italy

**13:51–14:06 Role of dermoscopy before and after treatment of melanoma and non-melanoma skin cancers**  
Zoe Apalla, Thessaloniki, Greece

**14:09–14:24 e-Health in the oncologic patients care**  
Josep Malvehy, Barcelona, Spain

**14:27–14:42 Dermoscopy of nested melanoma**  
Claudio Conforti, Trieste, Italy

**13:15–14:45** SY02  
PARIS

## Symposium Artificial intelligence in medical oncology, pathology and radiology

Chairpersons: Friedrich Overkamp, Berlin, Germany  
Richard Colling, Oxford, United Kingdom

**13:15–13:30** tbc

Friedrich Overkamp, Berlin, Germany

**13:33–13:48** Artificial intelligence in the interpretation of imaging examinations  
Andreas Maier, Erlangen, Germany

**13:51–14:06** Implementation of digital pathology into diagnostic practice  
Richard Colling, Oxford, United Kingdom

**14:09–14:24** Precision immunoprofiling by image analysis and artificial intelligence  
Victor H. Koelzer, Zurich, Switzerland

**14:27–14:42** Artificial intelligence in oncology  
Olivier Michielin, Lausanne, Switzerland

**13:15–14:45** SY03  
LONDON

## Symposium Epidemiologic trends in melanoma

Chairpersons: Alexander Katalinic, Luebeck, Germany  
David Whiteman, Brisbane, Australia

**13:15–13:30** Melanoma trends in Australia and Asia  
David Whiteman, Brisbane, Australia

**13:33–13:48** Melanoma trends in Africa  
Dagmar Whitaker, Cape Town, South Africa

**13:51–14:06** Melanoma trends in North America  
Aaron Thrift, Houston, USA

**14:09–14:24** Melanoma trends in South America  
Esther de Vries, Bogotá, Colombia

**14:27–14:42** Melanoma trends in Europe  
Alexander Katalinic, Luebeck, Germany



**13:15–14:45** SY04  
COPENHAGEN

## Symposium

### Actinic keratosis: recent treatment developments

Chairpersons: Maria Concetta Fagnoli, L'Aquila, Italy  
Nicole Kelleners-Smeets, Maastricht, The Netherlands

**13:15–13:30** Why treat actinic keratosis

Nicole Kelleners-Smeets, Maastricht, The Netherlands

**13:33–13:48** Lesion directed treatment: what's new

Rolf-Markus Szeimies, Recklinghausen, Germany

**13:51–14:06** Field directed treatment: what's new

Maria Concetta Fagnoli, L'Aquila, Italy

**14:09–14:24** Treatment of the immunosuppressed patient

Catherine Harwood, London, United Kingdom

**14:27–14:42** Chemoprevention of actinic keratosis / nonmelanoma skin cancers

Diona Damian, Sydney, Australia

**13:15–14:45** SY05  
AMSTERDAM

## Symposium

### Melanoma pathology – genomics and morphology

Chairpersons: Boris Bastian, San Francisco, USA  
Richard Scolyer, Sydney, Australia

**13:15–13:30** Spitz tumors, towards a unified definition

Iwei Yeh, San Francisco, USA

**13:33–13:48** Highly multiplex immunofluorescence and AI image analysis  
for personalised immunotherapy selection

James Wilmott, Sydney, Australia

**13:51–14:06** How do you recognise BAP1 inactivated melanocytic tumors  
and what is their significance?

Arnaud de la Fouchardière, Lyon, France

**14:09–14:24** UV-radiation and melanocytic neoplasia

Amaya Viros, Manchester, United Kingdom

**14:27–14:42** Similarities and differences between blue nevi and related tumors  
and uveal melanomas- are they twins or distant relatives?

Klaus Griewank, Mainz, Germany

**14:45–15:15**

Coffee Break

15:15–16:45 SY06  
ROME

## Symposium Dermoscopy 2: Difficult clinical scenarios

Chairpersons: Aimilios Lallas, Thessaloniki, Greece  
Caterina Longo, Reggio Emilia, Italy

- 15:15–15:30 **Face: dermoscopy hints**  
Caterina Longo, Reggio Emilia, Italy
- 15:33–15:48 **Acral and mucosal areas: what we should know**  
Aimilios Lallas, Thessaloniki, Greece
- 15:51–16:06 **Nail: the issue of pigmented band**  
Cristina Carrera, Barcelona, Spain
- 16:09–16:24 **Practical tips for an accurate digital monitoring**  
John Paoli, Gothenburg, Sweden
- 16:27–16:42 **Cases: the best and the worst**  
Philipp Tschandl, Vienna, Austria

15:15–16:45 SY07  
PARIS

## Symposium Surgery of metastatic melanoma

Chairpersons: Piotr Rutkowski, Warsaw, Poland  
Mario Santinami, Milan, Italy

- 15:15–15:30 **The current strategies in surgical therapy of stage III metastases**  
Piotr Rutkowski, Warsaw, Poland
- 15:33–15:48 **Locoregional approach in in-transit metastases**  
Dirk Gruenhagen, Rotterdam, The Netherlands
- 15:51–16:06 **The impact of systemic perioperative treatment on surgery in stage III melanoma**  
Mario Mandalá, Bergamo, Italy
- 16:09–16:24 **Surgery of distant metastases as elective treatment in selected cases or in combination with medical therapy: when and what**  
Merrick Ross, Houston, USA
- 16:27–16:45 **Case presentation and discussion**  
Alexander van Akkooi, Amsterdam, The Netherlands

15:15–16:45 SY08  
LONDON

## Symposium

### Squamous cell carcinoma: epidemiology and management

Chairpersons: Paola Queirolo, Genova, Italy  
Alexander Stratigos, Athens, Greece

**15:15–15:30 Epidemiology and prognostic classification**  
Alexander Stratigos, Athens, Greece

**15:33–15:48 Surgical approaches to common and high risk cSCC**  
Ricardo Vieira, Coimbra, Portugal

**15:51–16:06 Current medical management of advanced cSCC**  
Michael Migden, Houston, USA

**16:09–16:24 Ongoing and new approaches in high risk cSCC**  
Chrysalyne Schmults, Boston, USA

**16:27–16:42 Mechanisms of resistance to immunotherapy: how to overcome them?**  
Paolo Bossi, Milan, Italy

15:15–16:45 SY09  
COPENHAGEN

## Symposium

### Immunotherapies beyond checkpoint inhibition

Chairpersons: Paul Lorigan, Manchester, United Kingdom  
Jeffrey Weber, New York, USA

**15:15–15:30 IL-2 like drugs including NKTR-214 and ALKS 4230**  
Adi Diab, Houston, USA

**15:33–15:48 Adoptive cell therapy with TIL and other effector cells**  
Inge-Marie Svane, Copenhagen, Denmark

**15:51–16:06 Cytokines and growth factors including TGF-beta**  
Ignacio Melero, Pamplona, Spain

**16:09–16:24 Epigenetic modifiers**  
Ryan J. Sullivan, Massachusetts, USA

**16:27–16:42 New approaches with neoantigen vaccines/T-cell therapies**  
Samra Turajlic, London, United Kingdom



**15:15–16:45** SY10  
AMSTERDAM

## Symposium

### Genetic susceptibility of melanoma and cancer syndromes

Chairpersons: Nicholas Hayward, Brisbane, Australia  
Maria Teresa Landi, Bethesda, USA

**15:15–15:30** Genetic susceptibility in familial melanomas,  
with emphasis on families from Mediterranean countries  
Cristina Pellegrini, L'Aquila, Italy

**15:33–15:48** Novel high penetrant susceptibility genes from pooled analyses  
of worldwide melanoma-prone families  
Nicholas Hayward, Brisbane, Australia

**15:51–16:06** Non-coding genetic changes in 9p21-linked melanoma-prone families  
Antonia Pritchard, Inverness, United Kingdom

**16:09–16:24** Genetic susceptibility loci and related pathways from genome-wide  
association studies of melanoma and other traits  
Maria Teresa Landi, Bethesda, USA

**16:27–16:42** Melanoma and other tumors in BAP1-related syndrome  
Brigitte Bressac-de Paillerets, Paris, France

**15:15–16:45** SY11  
DUBLIN

## Symposium

### Registries for real world treatment data and outcome research

Chairpersons: Michael Weichenthal, Kiel, Germany  
Susana Puig, Barcelona, Spain

**16:45–17:00**

## Coffee Break

**17:00–18:00** SAT01  
ROME

## Satellite Symposium

**17:00–18:00** SAT02  
PARIS

## Satellite Symposium

**17:00–18:00** SAT03  
LONDON

## Satellite Symposium

17:00–18:00 SAT04  
COPENHAGEN

Satellite Symposium

17:00–18:00 SAT05  
AMSTERDAM

Satellite Symposium

17:00–18:00 SAT06  
DUBLIN

Satellite Symposium

18:00–20:00

Welcome Reception





# Scientific Programme

THURSDAY, APRIL 15

SCIENTIFIC PROGRAMME

	ROME	PARIS	LONDON
08:00	<b>08:00–09:15</b>	<b>08:00–09:15</b>	<b>08:00–09:15</b>
	<b>Symposium SY12</b> Controversies in dermato-oncology	<b>Symposium SY13</b> Interdisciplinary skin cancer centers: how they dealt with the Corona pandemic in different countries	<b>Symposium SY14</b> Molecular tumor board for skin cancer
09:00	<b>09:15–10:30</b>	<b>09:15–10:30</b>	<b>09:15–10:30</b>
	<b>Symposium SY16</b> Controversies in melanoma	<b>Symposium SY17</b> Management of acral lentiginous melanomas	<b>Symposium SY18</b> Merkel cell carcinoma: epidemiology, surgery and radiology
10:00			
	<b>10:30–11:00 Coffee Break</b>		
11:00	<b>11:00–12:30</b>		
	<b>Plenary Lecture PL02</b> Systemic versus intralesional immunotherapy – different biology?		
12:00			
	<b>12:30–12:45 Coffee Break</b>		
	<b>12:45–13:45</b>		
13:00	<b>Satellite Symposium SAT07</b> Platinum Sponsor (see page 58)		
	<b>13:45–14:15 Coffee Break</b>		
14:00			
	<b>14:15–15:15</b>	<b>14:15–15:15</b>	<b>14:15–15:15</b>
	<b>Symposium SY20</b> Advances in melanoma staging and prognosis: AJCC V8, integrative risk modeling, and beyond	<b>Symposium SY21</b> Cutaneous lymphomas: what is new?	<b>Symposium SY22</b> Epigenetic modulation in skin cancer
15:00	<b>15:15–16:15</b>	<b>15:15–16:15</b>	<b>15:15–16:15</b>
	<b>Symposium SY24</b> Primary prevention of skin cancer	<b>Symposium SY25</b> Ocular melanoma: similar and yet so different from other melanomas?	<b>Symposium SY26</b> New druggable targets in melanoma and keratinocyte skin cancer
16:00			
	<b>16:15–16:30 Coffee Break</b>		
	<b>16:30–17:30</b>	<b>16:30–17:30</b>	<b>16:30–17:30</b>
17:00	<b>Satellite Symposium SAT08</b>	<b>Satellite Symposium SAT09</b>	<b>Satellite Symposium SAT10</b>
18:00			

# THURSDAY APRIL 15

COPENHAGEN	AMSTERDAM	DUBLIN	
<b>08:00–09:15</b>	<b>08:00–09:15</b>	<b>08:00–09:15</b>	08:00
<b>Symposium SY15</b> Management of lentigo maligna melanomas	<b>Free Communications FC01</b>	<b>Patient Advocates MISC01</b>	
			09:00
<b>09:15–10:30</b>	<b>09:15–10:30</b>		
<b>Symposium SY19</b> Intralesional therapies of skin cancer	<b>Free Communications FC02</b>		10:00
			11:00
			12:00
			13:00
			14:00
<b>14:15–15:15</b>	<b>14:15–15:15</b>		
<b>Symposium SY23</b> Adoptive T-cell transfer	<b>Free Communications FC03</b>		15:00
<b>15:15–16:15</b>	<b>15:15–16:15</b>	<b>15:15–16:15</b>	
<b>Symposium SY27</b> Immunotherapy of merkel cell carcinoma	<b>Free Communications FC04</b>	<b>Symposium SY28</b> Management of melanoma in childhood and pregnancy	16:00
<b>16:30–17:30</b>	<b>16:30–17:30</b>	<b>16:30–17:30</b>	
<b>Satellite Symposium SAT11</b>	<b>Satellite Symposium SAT12</b>	<b>Satellite Symposium SAT13</b>	17:00
			18:00

THURSDAY, APRIL 15

SCIENTIFIC PROGRAMME

## THURSDAY, APRIL 15

08:00–09:15 SY12  
ROME

## Symposium

**Controversies in dermato-oncology**

Chairpersons: Catherine Harwood, London, United Kingdom  
Giovanni Pellacani, Modena, Italy

**Skin cancer screening saves lives !?**

08:00–08:12 **Yes:** Peter Mohr, Buxtehude, Germany

08:12–08:24 **No:** Ana-Maria Forsea, Bucharest, Romania

08:24–08:37 **Discussion**

**Sunscreens prevent skin cancer!?**

08:37–08:49 **Yes:** Veronique Del Marmol, Brussels, Belgium

08:49–09:01 **No:** Claus Garbe, Tuebingen, Germany

09:01–09:15 **Discussion**

08:00–09:15 SY13  
PARIS

## Symposium

**Interdisciplinary skin cancer centers: how they dealt with the Corona pandemic in different countries**

Chairpersons: Caroline Robert, Paris, France  
Richard Scolyer, Sydney, Australia  
Vernon Sondak, Tampa, USA

08:00–08:15 **Gustave Roussy Cancer Center in Paris**  
Caroline Robert, Paris, France

08:18–08:33 **Melanoma Institute Australia in Sydney**  
Richard Scolyer, Sydney, Australia

08:36–08:51 **Moffitt Cancer Center in Tampa**  
Vernon Sondak, Tampa, USA

08:54–09:09 **Netherlands Cancer Institute in Amsterdam**  
Christian Blank, Amsterdam, The Netherlands

**08:00–09:15** SY14  
LONDON

## Symposium Molecular tumor board for skin cancer

Chairpersons: Anja Bosserhoff, Erlangen, Germany  
Reinhard Dummer, Zurich, Switzerland

**08:00–08:15** **Oncogene rewiring in acrolentiginous melanoma**  
Boris Bastian, San Francisco, USA

**08:18–08:33** **How to use high resolution translational data in daily clinic**  
Reinhard Dummer, Zurich, Switzerland

**08:36–08:51** **Learning from early processes in melanoma development: molecules implicates in breaking of senescence**  
Anja Bosserhoff, Erlangen, Germany

**08:54–09:09** **Can serum markers guide treatment decisions?**  
Bastian Schilling, Wuerzburg, Germany

**08:00–09:15** SY15  
COPENHAGEN

## Symposium Management of lentigo maligna melanomas

Chairpersons: Joseph Alcalay, Tel Aviv, Israel  
Ricardo Vieira, Coimbra, Portugal

**08:00–08:15** **Diagnosis of lentigo maligna with handheld reflectance confocal microscopy: opportunity and pitfalls**  
Alon Scope, Tel Aviv, Israel

**08:18–08:33** **Staged excision techniques for lentigo maligna: an alternative to Mohs surgery?**  
Ricardo Vieira, Coimbra, Portugal

**08:36–08:51** **Surgical margins in lentigo maligna: how much is safe?**  
Eduardo Nagore, Valencia, Spain

**08:54–09:09** **Treating lentigo melanoma with Mohs surgery – yes, we can**  
Joseph Alcalay, Tel Aviv, Israel

**08:00–09:15** FC01  
AMSTERDAM

## Free Communications 1

Chairpersons: Elisabeth Livingstone, Essen, Germany  
Zeljko Mijuskovic, Belgrade, Serbia

**08:00–09:15** MISC01  
DUBLIN

## Patient Advocates

Chairpersons: Samantha Guild, Richmond, USA  
Gilliosa Spurrier, Teilhet, France



09:15–10:30 SY16  
ROME

## Symposium Controversies in melanoma

Chairpersons: Axel Hauschild, Kiel, Germany  
Mario Santinami, Milan, Italy

### Is surgery still standard of care in stage III/IV?

09:15–09:27 **Yes:** Merrick Ross, Houston, USA

09:27–09:39 **No:** Alexander Eggermont, Utrecht, The Netherlands

09:39–09:52 **Discussion**

### Is whole brain irradiation still standard of care?

09:52–10:04 **Yes:** Lars Bastholt, Odense, Denmark

10:04–10:16 **No:** Bernardo Rapoport, Johannesburg, South Africa

10:16–10:29 **Discussion**

09:15–10:30 SY17  
PARIS

## Symposium Management of acral lentiginous melanomas

Chairpersons: Taiki Isei, Osaka, Japan  
David Moreno-Ramirez, Seville, Spain

09:15–10:30 SY18  
LONDON

## Symposium Merkel cell carcinoma: epidemiology, surgery and radiology

Chairpersons: Roland Kaufmann, Frankfurt, Germany  
Celeste Lebbé, Paris, France

09:15–09:30 **Epidemiology of primary MCC**  
Andreas Stang, Essen, Germany

09:33–09:48 **MCC in immunosuppressed patient**  
Celeste Lebbé, Paris, France

09:51–10:06 **Best surgical modalities for the management of stage I to III MCC**  
Roland Kaufmann, Frankfurt, Germany

10:09–10:24 **Impact/role of radiotherapy in management of MCC**  
Paul Nghiem, Seattle, USA

**09:15–10:30** SY19  
COPENHAGEN

## Symposium Intralesional therapies of skin cancer

Chairpersons: Mark Middleton, Oxford, United Kingdom  
Chrysalyne Schmults, Boston, USA

**09:15–09:30** Established treatments – the lessons from history  
Chrysalyne Schmults, Boston, USA

**09:33–09:48** Talimogene laherparepvec T-VEC – the pathfinder  
Christoph Hoeller, Vienna, Austria

**09:51–10:06** Moving beyond T-VEC – novel virotherapies  
Mark Middleton, Oxford, United Kingdom

**10:09–10:24** Future targets for intralesional therapy  
Kevin Harrington, London, United Kingdom

**09:15–10:30** FC02  
AMSTERDAM

## Free Communications 2

Chairpersons: Pippa Corrie, Cambridge, United Kingdom  
Judit Oláh, Szeged, Hungary

**10:30–11:00**

Coffee Break

**11:00–12:30** PL02  
ROME

## Plenary Lecture Systemic versus intralesional immunotherapy – different biology?

Chairpersons: Lev Demidov, Moscow, Russia  
Rodrigo R. Munhoz, São Paulo, Brazil

**11:00–11:30** How immune cells kill tumor cells  
Thomas Gajewski, Chicago, USA

**11:30–12:00** Past, presence and future of intralesional drugs for skin cancer  
Olivier Michielin, Lausanne, Switzerland

**12:00–12:30** Microbiome transplantations versus diet  
Jennifer Wargo, Houston, USA

**12:30–12:45**

Coffee Break

12:45–13:45 SAT07  
ROME

Satellite Symposium  
**Platinum Sponsor**  
(see page 58)

13:45–14:15

Coffee Break

14:15–15:15 SY20  
ROME

Symposium  
**Advances in melanoma staging and prognosis: AJCC V8, integrative risk modeling, and beyond**

Chairpersons: Jeffrey Gershenwald, Houston, USA  
Michael Weichenthal, Kiel, Germany

14:15–15:15 SY21  
PARIS

Symposium  
**Cutaneous lymphomas: what is new?**

Chairpersons: Reinhard Dummer, Zurich, Switzerland  
Pietro Quaglino, Turin, Italy

14:15–14:30 **What is new in immunobiology and genomics in cutaneous lymphoma?**  
Martin Vermeer, Leiden, The Netherlands

14:35–14:50 **What is new in cutaneous B-cell lymphoma: from diagnostic to treatment?**  
Egle Ramelyte, Zurich, Switzerland

14:55–15:10 **What is new in cutaneous T-cell lymphoma: from diagnostic to treatment?**  
Julia Scarisbrick, Birmingham, United Kingdom

14:15–15:15 SY22  
LONDON

Symposium  
**Epigenetic modulation in skin cancer**

Chairpersons: Mitch Levesques, Zurich, Switzerland  
Michele Maio, Siena, Italy

14:15–14:30 **Rationale underlying epigenetic immuno-modulation of melanoma**  
Andrea Anichini, Milan, Italy

14:35–14:50 **Epigenetic immuno-modulation in the melanoma clinic**  
Anna Maria Di Giacomo, Siena, Italy

14:55–15:10 **Epigenetic modulation in non-melanoma skin cancers**  
Jürgen Becker, Essen, Germany

**14:15–15:15** SY23  
COPENHAGEN

## Symposium Adoptive T-cell transfer

Chairpersons: Jakob Schachter, Tel Aviv, Israel  
Inge Marie Svane, Copenhagen, Denmark

**14:15–14:30** Which melanoma patients can benefit from T-cell therapy?  
Inge Marie Svane, Copenhagen, Denmark

**14:35–14:50** Adaptive T-cell therapy – obstacles and opportunities  
Jakob Schachter, Tel Aviv, Israel

**14:55–15:10** T-cell therapy 2.0 – what can be achieved by genetic modifications?  
John Haanen, Amsterdam, The Netherlands

**14:15–15:15** FC03  
AMSTERDAM

## Free Communications 3

Chairpersons: NN, NN

**15:15–16:15** SY24  
ROM

## Symposium Primary prevention of skin cancer

Chairpersons: Hans Peter Soyer, Brisbane, Australia  
Dagmar Whitaker, Cape Town, South Africa

**15:15–15:30** Primary melanoma prevention in Australia: an update  
David Whiteman, Brisbane, Australia

**15:35–15:50** The sunscreen and vitamin D debate: where are we in 2021?  
Dagmar Whitaker, Cape Town, South Africa

**15:55–16:10** From primary to secondary prevention: a holistic concept  
Hans Peter Soyer, Brisbane, Australia



15:15–16:15 SY25  
PARIS

## Symposium

### Ocular melanoma: similar and yet so different from other melanomas?

Chairpersons: Martina Angi, Milan, Italy  
Nathalie Cassoux, Paris, France

15:15–15:30 **Diagnosis and treatment of uveal melanoma**  
Heinrich Heimann, Liverpool, United Kingdom

15:35–15:50 **Diagnosis and treatment of conjunctival melanoma**  
Martina Angi, Milan, Italy

15:55–16:10 **Pathology and therapeutic implications of ocular melanoma**  
Sarah E. Coupland, Liverpool, United Kingdom

15:15–16:15 SY26  
LONDON

## Symposium

### New druggable targets in melanoma and keratinocyte skin cancer

Chairpersons: Grant McArthur, Melbourne, Australia  
Martin McMahon, Salt Lake City, USA

15:15–16:15 SY27  
COPENHAGEN

## Symposium

### Immunotherapy of merkel cell carcinoma

Chairpersons: Jürgen Becker, Essen, Germany  
Paul Nghiem, Seattle, USA

15:15–15:30 **PD(L)-1 in MCC & options for addressing resistance with current tools**  
Jürgen Becker, Essen, Germany

15:35–15:50 **Adjuvant, neo-adjuvant & 'up-front' immunotherapy for loco-regionally advanced MCC**  
Mahtab Samimi, Tours, France

15:55–16:10 **Promising approaches and trials for advanced MCC**  
Paul Nghiem, Seattle, USA

15:15–16:15 FC04  
AMSTERDAM

## Free Communications 4

Chairpersons: NN, NN

<p><b>15:15–16:15</b> SY28 DUBLIN</p>	<p><b>Symposium</b> <b>Management of melanoma in pregnancy</b></p> <p>Chairpersons: Veronique Bataille, London, United Kingdom Selma Ugurel, Essen, Germany</p> <p><b>15:15–15:30</b> <b>Survey of management practices across Europe</b> Simone Ribero, Turin, Italy</p> <p><b>15:35–15:50</b> <b>Oestrogen progesterone receptors in melanoma and nevi</b> Emi Dika, Bologna, Italy</p> <p><b>15:55–16:10</b> <b>Does pregnancy affect melanoma prognosis?</b> Catarina Longo, Reggio, Italy</p>
<p><b>16:15–16:30</b></p>	<p><b>Coffee Break</b></p>
<p><b>16:30–17:30</b> SAT08 ROME</p>	<p><b>Satellite Symposium</b></p>
<p><b>16:30–17:30</b> SAT09 PARIS</p>	<p><b>Satellite Symposium</b></p>
<p><b>16:30–17:30</b> SAT10 LONDON</p>	<p><b>Satellite Symposium</b></p>
<p><b>16:30–17:30</b> SAT11 COPENHAGEN</p>	<p><b>Satellite Symposium</b></p>
<p><b>16:30–17:30</b> SAT12 AMSTERDAM</p>	<p><b>Satellite Symposium</b></p>
<p><b>16:30–17:30</b> SAT13 DUBLIN</p>	<p><b>Satellite Symposium</b></p>

# Scientific Programme

FRIDAY, APRIL 16

SCIENTIFIC PROGRAMME

	ROME	PARIS	LONDON
08:00	<b>08:00–09:00</b> <b>Symposium SY29</b> Controversies in radiotherapy	<b>08:00–09:00</b> <b>Symposium SY30</b> Basal cell carcinoma: epidemiology and management	<b>08:00–09:00</b> <b>Symposium SY31</b> Drug resistance to targeted therapies
09:00	<b>09:00–10:00</b> <b>Symposium SY33</b> Controversies in melanoma management	<b>09:00–10:00</b> <b>Symposium SY34</b> Liquid biopsy	<b>09:00–10:00</b> <b>Symposium SY35</b> Drug resistance to immune checkpoint inhibition
10:00	<b>10:00–10:30 Coffee Break</b>		
	<b>10:30–11:30</b> <b>Satellite Symposium SAT14</b> Platinum Sponsor <i>(see page 58)</i>		
11:00			
	<b>11:30–13:00</b> <b>Plenary Lecture PL03</b> Fundamental questions in dermato-oncology		
12:00			
13:00	<b>13:00–13:15 Coffee Break</b>		
	<b>13:15–14:15</b> <b>Satellite Symposium SAT15</b> Platinum Sponsor <i>(see page 58)</i>		
14:00			
	<b>14:15–14:30 Coffee Break</b>		
	<b>14:30–15:30</b> <b>Symposium SY38</b> Immune checkpoint inhibition for non-melanoma skin cancer	<b>14:30–15:30</b> <b>Symposium SY39</b> Management of brain metastasis	<b>14:30–15:30</b> <b>Symposium SY40</b> Melanocytic nevi: risks and management
15:00			
	<b>15:30–16:30</b> <b>Symposium SY42</b> Adjuvant treatment of melanoma	<b>15:30–16:30</b> <b>Symposium SY43</b> New devices for skin cancer diagnostics	<b>15:30–16:30</b> <b>Symposium SY44</b> Immune checkpoint inhibition in immunocompromised patients
16:00			
	<b>16:30–16:45 Coffee Break</b>		
	<b>16:45–17:45</b> <b>Satellite Symposium SAT16</b>	<b>16:45–17:45</b> <b>Satellite Symposium SAT17</b>	<b>16:45–17:45</b> <b>Satellite Symposium SAT18</b>
17:00			
18:00			

# FRIDAY APRIL 16

## COPENHAGEN

## AMSTERDAM

## DUBLIN

08:00–09:00	08:00–09:00		08:00
<b>Symposium SY32</b> Management of mucosal melanoma	<b>Free Communications FC05</b>		
09:00–10:00	09:00–10:00	09:00–10:00	09:00
<b>Symposium SY36</b> Regulation of drug access across the world	<b>Free Communications FC06</b>	<b>Symposium SY37</b> Quality assurance in dermatology-oncology	
			10:00
			11:00
			12:00
			13:00
			14:00
14:30–15:30	14:30–15:30		15:00
<b>Symposium SY41</b> Management of metastatic ocular melanoma	<b>Free Communications FC07</b>		
15:30–16:30	15:30–16:30	15:30–16:30	16:00
<b>Symposium SY45</b> Sentinel node biopsy: techniques and future perspectives	<b>Free Communications FC08</b>	<b>Symposium SY46</b> Controversies on vitamin D and photo protection	
16:45–17:45	16:45–17:45	16:45–17:45	17:00
<b>Satellite Symposium SAT19</b>	<b>Satellite Symposium SAT20</b>	<b>Satellite Symposium SAT21</b>	
			18:00

FRIDAY, APRIL 16

SCIENTIFIC PROGRAMME



## FRIDAY, APRIL 16

08:00–09:00 SY29  
ROME

### Symposium Controversies in radiotherapy

Chairpersons: Salvador Martin Algarra, Pamplona, Spain  
Mario Mandala, Bergamo, Italy

#### Radiotherapy elicits an abscopal effect!?

08:00–08:10 **Yes:** Philippe Saiag, Boulogne Billancourt, France

08:10–08:20 **No:** Jeffrey Weber, New York, USA

08:20–08:30 **Discussion**

#### Adjuvant radiotherapy should be abandoned!?

08:30–08:40 **Yes:** Paul Lorigan, Manchester, United Kingdom

08:40–08:50 **No:** Somasundaram Subramanian, Moscow, Russia

08:50–09:00 **Discussion**

08:00–09:00 SY30  
PARIS

### Symposium Basal cell carcinoma: epidemiology and management

Chairpersons: Matilda Bylaitė-Bučinskienė, Vilnius, Lithuania  
Ketty Peris, Rome, Italy

08:00–08:20 **Epidemiology and clinical-morphological correlation**  
Matilda Bylaitė-Bučinskienė, Vilnius, Lithuania

08:20–08:40 **Surgical procedures**  
Roland Kaufmann, Frankfurt, Germany

08:40–9:00 **Medical treatments**  
Ketty Peris, Rome, Italy

08:00–09:00 SY31  
LONDON

### Symposium Drug resistance to targeted therapies

Chairpersons: Grant McArthur, Melbourne, Australia  
Amaya Viros, Manchester, United Kingdom

**08:00–09:00** SY32  
COPENHAGEN

## Symposium Management of mucosal melanoma

Chairpersons: Christoffer Gebhardt, Hamburg, Germany  
Jun Guo, Beijing, China

**08:00–08:15** ICI and combination for mucosal melanoma, palliative and beyond  
Chuanliang Cui, Peking, China

**08:20–08:35** The clinical impact of the gut microbiota on immune checkpoint inhibitors in Asian mucosal and non-mucosal melanoma  
John Wen-Cheng Chang, Taoyuan, Taiwan

**08:40–08:55** Novel insights into molecular diagnostics in mucosal melanoma monitoring and treatment  
Christoffer Gebhardt, Hamburg, Germany

**08:00–09:00** FC05  
AMSTERDAM

## Free Communications 5

Chairpersons: NN, NN

**09:00–10:00** SY33  
ROME

## Symposium Controversies in melanoma management

Chairpersons: Ana Arance, Barcelona, Spain  
Axel Hauschild, Kiel, Germany

**All BRAF mutated patients should be primarily treated with BRAF/MEK inhibitors!?**

**09:00–09:10** Yes: Michael Postow, New York, USA

**09:10–09:20** No: Georgina Long, Sydney, Australia

**09:20–09:30** Discussion

**Intense follow-up evaluations improve survival!?**

**09:30–09:40** Yes: Ulrike Leiter, Tuebingen, Germany

**09:40–09:50** No: Alexander van Akkooi, Amsterdam, The Netherlands

**09:50–10:00** Discussion

09:00–10:00 SY34  
PARIS

## Symposium Liquid biopsy

Chairpersons: Bart Neyns, Brussels, Belgium  
Andreas Stang, Essen, Germany

09:00–09:15 **ctDNA analysis and applications in oncology**  
Helen Rizos, Sydney, Australia

09:20–09:35 **Genomic profiling of ctDNA for therapy monitoring and prognostic stratification in melanoma**  
Renata Varaljai, Essen, Germany

09:40–09:55 **Circulating tumor DNA for melanoma patients in clinical practice**  
Teofila Caplanusi Seremet, Lausanne, Switzerland

09:00–10:00 SY35  
LONDON

## Symposium Drug resistance to immune checkpoint inhibition

Chairpersons: Dirk Schadendorf, Essen, Germany  
Marisol Soengas, Madrid, Spain

09:00–09:15 **Predictors of response and resistance of PD1 checkpoint blockade**  
Bastian Schilling, Wuerzburg, Germany

09:20–09:35 **Importance of tertiary lymphoid structures for response to checkpoint blockade**  
Jennifer Wargo, Houston, USA

09:40–09:55 **Imaging and targeting (pre)metastatic niches in melanoma**  
Marisol Soengas, Madrid, Spain

09:00–10:00 SY36  
COPENHAGEN

## Symposium Regulation of drug access across the world

Chairpersons: Gabriela Cinat, Buenos Aires, Argentina  
Lidija Kandolf-Sekulovic, Belgrade, Serbia

14:30–14:45 **Existing gaps in drug access in Europe and current solutions**  
Lidija Kandolf-Sekulovic, Belgrade, Serbia

14:50–15:05 **Regulation of drug access, current obstacles and successful schemes in USA**  
Sanjiv Agarwala, Philadelphia, USA

15:10–15:25 **Drug access schemes in LATAM countries**  
Gabriela Cinat, Buenos Aires, Argentina

**09:00–10:00** FC06  
AMSTERDAM

## Free Communications 6

Chairpersons: NN, NN

**09:00–10:00** SY37  
DUBLIN

## Symposium Quality assurance in dermatology

Chairpersons: Ana-Maria Forsea, Bucharest, Romania  
Vernon Sondak, Tampa, USA

**09:00–09:15** Certification in dermatology  
Ana-Maria Forsea, Bucharest, Romania

**09:20–09:35** Interdisciplinary skin cancer centers in Germany  
Thomas Eigentler, Tuebingen, Germany

**09:40–09:55** Quality assurance in US cancer centers  
Vernon Sondak, Tampa, USA

**10:00–10:30**

Coffee Break

**10:30–11:30** SAT14  
ROME

## Satellite Symposium Platinum Sponsor

(see page 58)

**11:30–13:00** PL03  
ROME

## Plenary Lecture Fundamental questions in dermatology

Chairpersons: Caroline Robert, Paris, France  
Jedd Wolchok, New York, USA

**11:30–12:00** UV induced DNA-damage in skin cancer: mechanisms and significance  
Richard Marais, Manchester, United Kingdom

**12:00–12:30** Cure of metastatic melanoma on the horizon?  
Georgina Long, Sydney, Australia

**12:30–13:00** Scientific rationale for combined or sequential treatment of melanoma  
Olivier Michielin, Lausanne, Switzerland

**13:00–13:15**

Coffee Break

**13:15–14:15** SAT15  
ROME

## Satellite Symposium Platinum Sponsor

(see page 58)



14:15–14:30

Coffee Break

14:30–15:30 SY38  
ROME

### Symposium Immune checkpoint inhibition for non-melanoma skin cancer

Chairpersons: Ralf Gutzmer, Hanover, Germany  
Christoph Höller, Vienna, Austria

**14:30–14:45 Merkel cell carcinoma**  
Paul Nghiem, Seattle, USA

**14:50–15:05 Basal cell carcinoma**  
Ralf Gutzmer, Hanover, Germany

**15:10–15:25 Squamous cell carcinoma**  
Michael Migden, Houston, USA

14:30–15:30 SY39  
PARIS

### Symposium Management of brain metastasis

Chairpersons: Michael Davies, Houston, USA  
Friedegund Meier, Dresden, Germany

**14:30–14:45 Use of immunotherapy for melanoma brain metastases**  
Michael Postow, New York, USA

**14:50–15:05 Use of targeted therapy and combinatorial strategies for brain metastases**  
Friedegund Meier, Dresden, Germany

**15:10–15:25 New insights into the unique features and pathogenesis of brain metastases**  
Michael Davies, Houston, USA

14:30–15:30 SY40  
LONDON

### Symposium Melanocytic nevi: risks and management

Chairpersons: Jean Jacques Grob, Marseille, France  
Jason Rivers, Vancouver, Canada

**14:30–15:30** SY41  
COPENHAGEN

## Symposium Management of metastatic ocular melanoma

Chairpersons: Paul Nathan, London, United Kingdom  
Bastian Schilling, Wuerzburg, Germany

**09:00–09:15** Which patients should be considered for  
hepatic local treatment and why?  
Matthew Wheeler, Southampton, United Kingdom

**09:20–09:35** Should immune checkpoint inhibitors be used in metastatic OM?  
Bastian Schilling, Wuerzburg, Germany

**09:40–09:55** The role of ImmTacs in metastatic OM  
Paul Nathan, London, United Kingdom

**14:30–15:30** FC07  
AMSTERDAM

## Free Communications 7

Chairpersons: NN, NN

**15:30–16:30** SY42  
ROME

## Symposium Adjuvant treatment of melanoma

Chairpersons: Sanjiv Agarwala, Philadelphia, USA  
Erika Richtig, Graz, Austria

**15:30–15:45** Adjuvant immunotherapy  
Jeffrey Weber, New York, USA

**15:50–16:05** Adjuvant targeted therapy  
Georgina Long, Sydney, Australia

**16:10–16:25** Who needs adjuvant treatment when melanoma can be cured  
by neo-adjuvant or palliative treatments?  
Christian Blank, Amsterdam, The Netherlands

**15:30–16:30** SY43  
PARIS

## Symposium New devices for skin cancer diagnostics

Chairpersons: Allan C. Halpern, New York, USA  
Josep Malvehy, Barcelona, Spain

**15:30–15:45** **Total body photography (3D/2D) and artificial intelligence**  
Allan C. Halpern, New York, USA

**15:50–16:05** **In vivo confocal reflectance microscopy and tomography**  
Giovanni Pellacani, Modena, Italy

**16:10–16:25** **LC-OCT, nevisense and optical coherence for fast pathology ex-vivo**  
Josep Malvehy, Barcelona, Spain

**15:30–16:30** SY44  
LONDON

## Symposium Immune checkpoint inhibition in immunocompromised patients

Chairpersons: Brigitte Dreno, Nantes, France  
Eggert Stockfleth, Bochum, Germany

**15:30–15:45** **Anti-PD-1/PD-L1 immunotherapy in transplant patients with advanced non melanoma skin cancer**  
Martin Tio, Sydney, Australia

**15:50–16:05** **How to manage anti-PD-1/anti-CTLA-4 immunotherapy in transplant patients with metastatic melanoma**  
Brigitte Dreno, Nantes, France

**16:10–16:25** **New treatment options in the prevention of skin tumors in organ transplant recipients**  
Eggert Stockfleth, Bochum, Germany

**15:30–16:30** SY45  
COPENHAGEN

## Symposium Sentinel node biopsy: techniques and future perspectives

Chairpersons: Alexander van Akkooi, Amsterdam, The Netherlands  
Alberto Wainstein, Belo Horizonte, Brazil

**15:30–15:45** **Does the sentinel lymph node biopsy by itself have any therapeutic benefit?**  
Mark Faries, Los Angeles, USA

**15:50–16:05** **What will be the gold standard technics to sentinel lymph node biopsy approach for the next years?**  
Jeffrey Gershenwald, Houston, USA

**16:10–16:25** **Which molecular, immunological or mulitpanel biomarkers are useful in clinical practice?**  
Daniela Massi, Florence, Italy

15:30–16:30 <b>FC08</b> AMSTERDAM	<b>Free Communications 8</b>  Chairpersons: NN, NN
15:30–16:30 <b>SY46</b> DUBLIN	<b>Symposium</b> <b>Controversies on vitamin D and photo protection</b>  Chairpersons: Veronique Bataille, London, United Kingdom Matilda Bylaitė-Bučinskienė, Vilnius, Lithuania
16:30–16:45	<b>Coffee Break</b>
16:45–17:45 <b>SAT16</b> ROME	<b>Satellite Symposium</b>
16:45–17:45 <b>SAT17</b> PARIS	<b>Satellite Symposium</b>
16:45–17:45 <b>SAT18</b> LONDON	<b>Satellite Symposium</b>
16:45–17:45 <b>SAT19</b> COPENHAGEN	<b>Satellite Symposium</b>
16:45–17:45 <b>SAT20</b> AMSTERDAM	<b>Satellite Symposium</b>
16:45–17:45 <b>SAT21</b> DUBLIN	<b>Satellite Symposium</b>

# Scientific Programme

SATURDAY, APRIL 17

SCIENTIFIC PROGRAMME

	ROME	PARIS	LONDON
08:00			
09:00			
	09:15–10:15	09:15–10:15	09:15–10:15
	<b>Symposium SY47</b> Evidence-based skin cancer guidelines	<b>Symposium SY48</b> Highlights from AACR	<b>Symposium SY49</b> Management of adverse events in immuno-oncology
10:00			
	10:15–11:15	10:15–11:15	10:15–11:15
	<b>Symposium SY52</b> Neoadjuvant treatment of melanoma	<b>Symposium SY53</b> Artificial intelligence in dermatology	<b>Symposium SY54</b> Management of adverse events in targeted therapies
11:00			
	11:15–11:45 Coffee Break		
	11:45–12:45	11:45–12:45	11:45–12:45
12:00	<b>Symposium SY56</b> Dermoscopy 3	<b>Symposium SY57</b> Cancer survivorship	<b>Symposium SY58</b> Melanoma and aging
	12:45–13:00 Farewell		
13:00			
14:00			
15:00			
16:00			
17:00			
18:00			



# SATURDAY APRIL 17

COPENHAGEN

AMSTERDAM

DUBLIN

			08:00
			09:00
<b>09:15–10:15</b>	<b>09:15–10:15</b>		
<b>Symposium SY50</b> Prognostic and predictive biomarkers in melanoma	<b>Symposium SY51</b> Management of rare skin cancers		10:00
<b>10:15–11:15</b>	<b>10:15–11:15</b>		
<b>Symposium SY55</b> Is it as simple as making a cold tumor hot?	<b>How to communicate with cancer patients?</b> MISC02		11:00
<b>11:45–12:45</b>	<b>11:45–12:45</b>		12:00
<b>Symposium SY59</b> Electrochemotherapy in dermatology-oncology	<b>How to train young doctors in dermatology-oncology?</b> MISC03		
			13:00
			14:00
			15:00
			16:00
			17:00
			18:00

SATURDAY, APRIL 17

SCIENTIFIC PROGRAMME

# SATURDAY, APRIL 17

SATURDAY, APRIL 17

SCIENTIFIC PROGRAMME

09:15–10:15 SY47  
ROME

## Symposium

### Evidence-based skin cancer guidelines

Chairpersons: Thomas Eigentler, Tuebingen, Germany  
Teresa Petrella, Toronto, Canada

09:15–09:30 **Adjuvant and stage IV therapies in the Canadian Melanoma Guideline**  
Teresa Petrella, Toronto, Canada

09:35–09:50 **Adjuvant and stage IV therapies in the German Melanoma Guideline**  
Thomas Eigentler, Tuebingen, Germany

09:55–10:10 **Adjuvant and stage IV therapies in the US Melanoma Guideline**  
Jeffrey Weber, New York, USA

09:15–10:15 SY48  
PARIS

## Symposium

### Highlights from AACR

Chairpersons: Helen Gogas, Athens, Greece  
Michael Postow, New York, USA

09:15–10:15 SY49  
LONDON

## Symposium

### Management of adverse events in immuno-oncology

Chairpersons: Carola Berking, Erlangen, Germany  
Gabriela Cinat, Buenos Aires, Argentina

09:15–09:30 **Serious and rare systemic adverse events: experience from an international registry**  
Lucie Heinzerling, Erlangen, Germany

09:35–09:50 **Management of colitis beyond corticosteroids**  
John Haanen, Amsterdam, The Netherlands

09:55–10:10 **Biomarkers of immune-related adverse events in melanoma**  
Jessica Hassel, Heidelberg, Germany

**09:15–10:15** SY50  
COPENHAGEN

## Symposium Prognostic and predictive biomarkers in melanoma

Chairpersons: Jochen Utikal, Mannheim, Germany  
Jedd Wolchok, New York, USA

**09:15–09:30** **Role of MDSCs as prognostic and predictive biomarkers in melanoma**  
Viktor Umansky, Heidelberg, Germany

**09:35–09:50** **Primary tumor-based gene expression profile (GEP) tests in melanoma: ready for clinical use as a prognostic biomarker?**  
Michael Marchetti, New York, USA

**09:55–10:10** **PD-L1 as predictive marker of immunotherapy**  
Selma Ugurel, Essen, Germany

**09:15–10:15** SY51  
AMSTERDAM

## Symposium Management of rare skin cancers

Chairpersons: Maria Concetta Fargnoli, L'Aquila, Italy  
Philippe Saiag, Boulogne Billancourt, France

**10:15–11:15** SY52  
ROME

## Symposium Neoadjuvant treatment of melanoma

Chairpersons: Paolo Ascierto, Naples, Italy  
Christian Blank, Amsterdam, The Netherlands

**10:15–10:30** **Neoadjuvant checkpoint inhibitor combinations**  
Christian Blank, Amsterdam, The Netherlands

**10:35–10:50** **Neoadjuvant combinations with targeted therapies**  
Rodabe Amaria, Austin, USA

**10:55–11:10** **Neoadjuvant combinations with innate immunity stimulation**  
Diwakar Davar, Pittsburgh, USA

10:15–11:15 SY53  
PARIS

## Symposium Artificial intelligence in dermatology

Chairpersons: Holger Hänßle, Heidelberg, Germany  
Harald Kittler, Vienna, Austria

10:15–10:30 **State-of-the-art of artificial intelligence in dermatology**  
Josep Malvehy, Barcelona, Spain

10:35–10:50 **Limitations and pitfalls of artificial intelligence in dermatology**  
Holger Hänßle, Heidelberg, Germany

10:55–10:10 **Human-computer collaboration for skin cancer diagnosis**  
Harald Kittler, Vienna, Austria

10:15–11:15 SY54  
LONDON

## Symposium Management of adverse events in targeted therapies

Chairpersons: Katharina Kähler, Kiel, Germany  
Van Anh Nguyen, Innsbruck, Austria

10:15–10:30 **Side effects associated with targeted therapies**  
Van Anh Nguyen, Innsbruck, Austria

10:35–10:50 **Managing patients on targeted therapies**  
Katharina Kähler, Kiel, Germany

10:55–10:10 **Challenging cases**  
Jakob Schachter, Tel Aviv, Israel

10:15–11:15 SY55  
COPENHAGEN

## Symposium Is it as simple as making a cold tumor hot?

Chairpersons: Stephan Grabbe, Mainz, Germany  
John Haanen, Amsterdam, The Netherlands

10:15–10:30 **Ex vivo tumor fragment platform to investigate cold and hot tumors**  
Daniela Thommen, Amsterdam, The Netherlands

10:35–10:50 **The complexity of changing cold tumors**  
Stefani Spranger, Cambridge, USA

10:55–10:10 **Improving susceptibility to immunotherapy using intralesional therapies**  
Robert Andtbacka, Edison, USA

**10:15–11:15** **MISC02**  
AMSTERDAM

## **How to communicate with cancer patients?**

Chairpersons: Thomas Eigentler, Tuebingen, Germany  
Christoph Höller, Vienna, Austria

**11:15–11:45**

## **Coffee Break**

**11:45–12:45** **SY56**  
ROME

## **Symposium Dermoscopy 3: Total body photography, digital dermatoscopy and scanners: indications and procedures**

Chairpersons: Marcus Maia, São Paulo, Brazil  
Luc Thomas, Lyon, France

**11:45–12:00** **Cost-efficiency evaluation of digital dermoscopy**  
Marcus Maia, São Paulo, Brazil

**12:05–12:20** **Strategies using digital dermoscopy and total body photography**  
Luc Thomas, Lyon, France

**12:25–12:40** **Past, present, and future of artificial intelligence in dermoscopy**  
Holger Hänßle, Heidelberg, Germany

**11:45–12:45** **SY57**  
PARIS

## **Symposium Cancer survivorship**

Chairpersons: Alexander Katalinic, Luebeck, Germany  
Somasundaram Subramanian, Moscow, Russia

**11:45–12:45** **SY58**  
LONDON

## **Symposium Melanoma and aging**

Chairpersons: Grant McArthur, Melbourne, Australia  
Marisol Soengas, Madrid, Spain



**11:45–12:45** SY59  
COPENHAGEN

## Symposium Electrochemotherapy in dermatology

Chairpersons: Piotr Rutkowski, Warsaw, Poland  
Alessandro Testori, Milan, Italy

**11:45–12:00** H&N mucosal cancers treated with ECT  
Marco Benazzo, Pavia, Italy

**12:05–12:20** Visceral approach with ECT  
Attila Kovács, Bonn, Germany

**12:25–12:40** ECT in combination with ICP inhibitors  
Judit Oláh, Szeged, Hungary

**11:45–12:45** MISC03  
AMSTERDAM

## How to train young doctors in dermatology?

Chairpersons: Jessica Hassel, Heidelberg, Germany  
Van Anh Nguyen, Innsbruck, Austria

**12:45–13:00**  
ROME

## Farewell

Claus Garbe, Tuebingen, Germany

## NOTES

**SATURDAY, APRIL 17**

SCIENTIFIC PROGRAMME

## Sponsored Symposia

### THURSDAY, APRIL 15

12:45–13:45  
ROME

Platinum Sponsor



### FRIDAY, APRIL 16

10:30–11:30  
ROME

Platinum Sponsor



13:15–14:15  
ROME

Platinum Sponsor



## PLATINUM SPONSORS



## GOLD SPONSOR



## BRONZE SPONSOR



## SPONSORS AND EXHIBITORS

